Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 5/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525944 | 0.84 | MAPT (0.36) | GAAMAPTHPGDRAB9AP2RX7 | |
| SCHEMBL6657986 | 0.76 | LTA4H (0.52) | LTA4HMAOB | |
| SCHEMBL30596225 | 0.76 | KMT2A (0.49) | GAAMAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4513449 | 0.75 | ALDH1A1 (0.44) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL237029 | 0.71 | KDM1A (0.46) | KDM1AMAOAMAOBSMN1; SMN2 | |
| SCHEMBL237030 | 0.71 | KDM1A (0.46) | KDM1AMAOAMAOBSMN1; SMN2 | |
| SCHEMBL2755941 | 0.71 | KDM1A (0.46) | KDM1AMAOAMAOBSMN1; SMN2 | |
| SCHEMBL9158253 | 0.70 | MAPT (0.53) | GAAMAPTHPGDRAB9AKDM1A | |
| SCHEMBL4525941 | 0.69 | MEN1 (0.53) | GAAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL18067963 | 0.69 | MAPT (0.43) | GAAMAPTHPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | GAA 3392/4885MAPT 3649/4885HPGD 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.